Monteiro, Fernando Sabino Marques; Fiala, Ondřej; Massari, Francesco; Myint, Zin W; Kopecky, Jindrich; Kucharz, Jakub; Büttner, Thomas; Grande, Enrique; Bourlon, Maria Teresa; Molina-Cerrillo, Javier; Pichler, Renate; Buchler, Tomas; Seront, Emmanuel; Ansari, Jawaher; Bamias, Aristotelis; Bhuva, Dipen; Vau, Nuno; Porta, Camillo; Fay, Andre Poisl; Santoni, Matteo, Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study, «CLINICAL GENITOURINARY CANCER», 2023, 1, pp. 1 - 13 [articolo]
Melotti, Sofia; Ambrosi, Francesca; Franceschini, Tania; Giunchi, Francesca; Filippo, Giorgia Di; Franchini, Eugenia; Massari, Francesco; Mollica, Veronica; Tateo, Valentina; Bianchi, Federico Mineo; Colecchia, Maurizio; Acosta, Andres Martin; Lobo, João; Fiorentino, Michelangelo; Ricci, Costantino, TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis, «PATHOLOGY RESEARCH AND PRACTICE», 2023, 247, pp. 154540 - 154546 [articolo]Open Access
Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco, TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab, «PATHOLOGY RESEARCH AND PRACTICE», 2023, 253, pp. 155008 - 155013 [articolo]
Nuvola, Giacomo; Mollica, Veronica; Massari, Francesco; Suárez, Cristina, The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors, «IMMUNOTHERAPY», 2023, 1, pp. 1 - 6 [articolo]
Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rosellini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco, The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study, «CLINICAL AND EXPERIMENTAL MEDICINE», 2023, 1, pp. 1 - 11 [articolo]
Monteiro, Fernando Sabino Marques; Soares, Andrey; Rizzo, Alessandro; Santoni, Matteo; Mollica, Veronica; Grande, Enrique; Massari, Francesco, The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis, «CLINICAL GENITOURINARY CANCER», 2023, 23, pp. 1 - 10 [articolo]
Fiala, Ondřej; Buti, Sebastiano; Takeshita, Hideki; Okada, Yohei; Massari, Francesco; Palacios, Georgia Anguera; Dionese, Michele; Scagliarini, Sarah; Büttner, Thomas; Fornarini, Giuseppe; Myint, Zin W; Galli, Luca; Souza, Vinicius Carrera; Pichler, Renate; De Giorgi, Ugo; Quiroga, María Natalia Gandur; Gilbert, Danielle; Popovic, Lazar; Grande, Enrique; Mammone, Giulia; Berardi, Rossana; Crabb, Simon J; Molina-Cerrillo, Javier; Freitas, Marcelo; Luz, Murilo; Iacovelli, Roberto; Calabrò, Fabio; Tural, Deniz; Atzori, Francesco; Küronya, Zsófia; Chiari, Rita; Campos, Saul; Caffo, Orazio; Fay, André P; Kucharz, Jakub; Zucali, Paolo Andrea; Rinck, José Augusto; Zeppellini, Annalisa; Bastos, Diogo Assed; Aurilio, Gaetano; Mota, Augusto; Trindade, Karine; Ortega, Cinzia; Sade, Juan Pablo; Rizzo, Mimma; Vau, Nuno; Giannatempo, Patrizia; Barillas, Allan; Monteiro, Fernando Sabino Marques; Dauster, Breno; Cattrini, Carlo; Nogueira, Lucas; de Carvalho Fernandes, Roni; Seront, Emmanuel; , Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study, «CANCER IMMUNOLOGY, IMMUNOTHERAPY», 2023, 1, pp. 1 - 18 [articolo]
Ricci, Costantino; Ambrosi, Francesca; Franceschini, Tania; Giunchi, Francesca; Franchini, Eugenia; Massari, Francesco; Mollica, Veronica; Bianchi, Federico Mineo; Colecchia, Maurizio; Acosta, Andres Martin; Fiorentino, Michelangelo, Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma?, «PATHOLOGY, RESEARCH AND PRACTICE», 2023, 241, pp. 154269 - 154269 [articolo]
Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco, A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy, «PATHOLOGY RESEARCH AND PRACTICE», 2022, 236, pp. 153978 - 153983 [articolo]
Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F., A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents, «ANTI-CANCER DRUGS», 2022, 33, pp. e43 - e51 [articolo]
Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y.; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A., Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial, «THE LANCET», 2022, 400, pp. 1103 - 1116 [articolo]Open Access
Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F., Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study, «CANCERS», 2022, 14, Article number: 4142, pp. 1 - 9 [articolo]Open Access
Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System, «CANCERS», 2022, 14, Article number: 4610, pp. 1 - 13 [articolo]Open Access
Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N., Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis, «TUMORI», 2022, na, pp. 030089162210903 - 030089162210909 [articolo]
Rebuzzi S.E.; Cerbone L.; Signori A.; Santoni M.; Murianni V.; De Giorgi U.; Procopio G.; Porta C.; Milella M.; Basso U.; Massari F.; Maruzzo M.; Iacovelli R.; Battelli N.; Carmisciano L.; Banna G.L.; Buti S.; Fornarini G., Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2022, 14, Article number: 17588359221079580, pp. 1 - 12 [articolo]Open Access
